Investment Rating - The report gives the company an "Accumulate" rating for the first time [6][14]. Core Viewpoints - The company is a leading domestic player in cardiac electrophysiology, providing a comprehensive three-dimensional cardiac electrophysiology solution, with strong technical barriers and a complete product matrix [4][14]. - The domestic electrophysiology market is experiencing rapid growth, driven by favorable policies and increasing demand for innovative technologies, with the company positioned to capture significant market share [2][3]. Company Overview - The company, established in 2010, focuses on innovative medical devices for electrophysiology intervention and ablation therapy, becoming the first domestic manufacturer to offer a complete solution in this field [21]. - The company has a stable shareholding structure, with no single shareholder holding more than 10%, ensuring balanced governance [24][27]. Financial Performance - The company is projected to achieve revenue of 413 million yuan in 2024, representing a year-on-year growth of 25.51%, and a net profit of 52 million yuan, with a staggering growth of 815.36% [5][14]. - Earnings per share (EPS) are forecasted to be 0.13, 0.18, and 0.26 yuan for 2025, 2026, and 2027 respectively, with corresponding price-to-earnings (P/E) ratios of 187, 131, and 88 [4][5]. Market Dynamics - The domestic electrophysiology market is expected to grow significantly, with the market share of foreign brands decreasing from 93% in 2020 to 72% in 2024, indicating a strong trend towards domestic substitution [2][3]. - The company has successfully participated in multiple provincial procurement programs, demonstrating its clinical recognition and market competitiveness [2][3]. Product Development - The company has a comprehensive product line covering two-dimensional and three-dimensional systems, with several products filling domestic gaps and matching foreign competitors in performance [3][4]. - The company is actively developing new products in emerging fields such as pulse ablation and renal artery treatment, enhancing its growth potential [3][12]. Profitability Forecast - The company’s revenue from catheter products is expected to grow at rates of 16.00%, 28.00%, and 27.00% from 2025 to 2027, driven by increased market penetration and procurement benefits [10]. - The gross margin is anticipated to stabilize above 60% starting in 2025, following the launch of high-margin new products [11].